"Prednisone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
| Descriptor ID |
D011241
|
| MeSH Number(s) |
D04.210.500.745.432.719.702
|
| Concept/Terms |
Prednisone- Prednisone
- Dehydrocortisone
- delta-Cortisone
|
Below are MeSH descriptors whose meaning is more general than "Prednisone".
Below are MeSH descriptors whose meaning is more specific than "Prednisone".
This graph shows the total number of publications written about "Prednisone" by people in this website by year, and whether "Prednisone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 5 | 7 |
| 1996 | 2 | 8 | 10 |
| 1997 | 0 | 7 | 7 |
| 1998 | 4 | 7 | 11 |
| 1999 | 3 | 2 | 5 |
| 2000 | 0 | 2 | 2 |
| 2001 | 4 | 2 | 6 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 3 | 4 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 5 | 5 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 6 | 7 |
| 2010 | 1 | 9 | 10 |
| 2011 | 0 | 2 | 2 |
| 2012 | 2 | 3 | 5 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 5 | 7 |
| 2015 | 2 | 2 | 4 |
| 2016 | 0 | 5 | 5 |
| 2017 | 3 | 5 | 8 |
| 2018 | 0 | 5 | 5 |
| 2019 | 3 | 2 | 5 |
| 2020 | 4 | 4 | 8 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisone" by people in Profiles.
-
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
-
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. J Clin Oncol. 2024 Feb 01; 42(4):467-480.
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 05 04; 141(18):2194-2205.
-
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 06 20; 41(18):3352-3362.
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
-
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539.
-
Intermittent glucocorticoid treatment enhances skeletal muscle performance through sexually dimorphic mechanisms. J Clin Invest. 2022 03 15; 132(6).
-
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 02; 21(1):659.
-
IgG 4 Autoimmune Hepatitis Presenting as Idiopathic Hypereosinophilia Syndrome. Hepatology. 2021 04; 73(4):1615-1617.
-
A Teenager With Leg Rash, Fevers, and Positional Dyspnea. Clin Pediatr (Phila). 2020 11; 59(13):1214-1218.